China economy has experienced consistent GDP growth of 9% in the last decade, and the Chinese Pharmaceutical Market has increased total sales by approx. 17% with an average CAGR of 18%. The market has in 10 years increased from RMB 18 billion to RMB 74 billion. It is estimated that the market will keep double-digits growth at least another decade.

Many multinational pharmaceutical companies are expanding their investments in China. For years, they have taken a bigger-is-better approach on the sales field force and marketing programs. However, the discrepancy between growth in investment and increase in prescription has made the return of investment one of the most important challenges.

Other challenges confronting the industry are weak product pipelines, product withdrawals, external regulatory changes, cost constraints and financial pressure from investors.

In the past ten years Loudon China has worked in the Chinese market to provide SFE services to major pharmaceutical companies in order to improve their effectiveness in sales and marketing. Key services we provide include:

KPI Measurement

Share Of Voice (SOV) Measurement

Targeting and Segmentation

Sales Force Reallocation and Optimization